Skip to main content
. 2021 Dec 17;23(2):51. doi: 10.3892/ol.2021.13169

Figure 2.

Figure 2.

MEK inhibitor (trametinib) suppresses CD155 and CD112 surface expression of most AML cell lines (MOLM-13, MV-4-11, THP-1, KG-1) examined. Histograms of CD155 and CD112 expression in AML cell lines treated with trametinib (10 and 100 nM: yellow and green, respectively)/DMSO (red) for 48 h. AML, acute myeloid leukemia; MFI, mean fluorescence intensity.